Kraig Biocraft Laboratories (OTCQB:KBLB) is attempting to commercialize Spider Silk and completed the spring production trials, with the results exceeding expectations.

Spider Silk has long been sought after as the "Holy Grail," of materials and is tougher than Kevlar, yet the fibers can be woven into garments.

Spider Silk applications range from mundane clothing to high performance athletic or military protective textiles, cosmetics, engineering textiles, fiber optics, and medical applications, fibers, ligaments, skin grafts and tissue engineering. It's thought that, someday, spider silk will be molded into a biodegradable "bioplastic" and help relieve the harmful plastic waste cycle.

“The BAM-1 parental lines have proven to be the strongest and most resilient we have ever fielded,” commented Company founder and CEO, Kim Thompson. “This production run greatly exceeded our targets and has prepared us for the next phase of our business plan. With these production trials successfully concluded, we are now aggressively implementing the next phase of our business plan, which will expand our operations and target multiple production locations in multiple countries.”

Thompson and world-renowned sericulture expect, Dr. Nirmal Kumar, spent the last two months directly overseeing Kraig's trials, selecting facilities for expansion, reviewing operational protocols, and meeting with officials and business leaders regarding the Company’s immediate plans.

Thompson is now returning to the U.S. to enact the next stages of its spider silk production expansion plan and complete the Company’s transition from a technology developer to a large-scale spider silk manufacturer.

Hims & Hers Health (NYSE:HIMS) reported its first quarter 2024 financial results in a shareholder letter that is posted at www.investors.hims.com.

Highlights include a 46% year-over-year increase in quarterly revenue to $278.2 million, 41% year-over-year quarterly subscribers growth to 1.7 million, and it raised full year 2024 guidance to a range of $1.20 billion to $1.23 billion.

Hims & Hers Health's CFO, Yemi Okupe, commented, “The business continues to generate robust performance across our operations as we execute on our mission to make the world feel great through the power of better health. Our ability to bring a record number of net new subscribers to the platform while simultaneously driving over 400 basis points of marketing leverage is a testament to the formidable model we are building. We are confident that ongoing investment in a broad offering of high quality, personalized solutions at affordable prices, combined with a trusted brand and best-in-class technology platform, will position us to achieve consistent top and bottom line growth for the foreseeable future. We have updated our full year outlook to reflect the ongoing business momentum and efficiency improvements we are experiencing. These improvements also further bolster our confidence in reaching our long-term Adjusted EBITDA margin goals of 20%-30%.”

Nuwellis (NASDAQ:NUWE) also reported its first quarter 2024 financial results

The first quarter highlights include a 2% increase over the prior-year quarterly revenue to $1.9 million and it grew gross margin to 64.1%, compared to 58.4% in the prior year period.

"We are pleased to see firm utilization, led by Pediatrics and in Critical Care, driving first-quarter revenue," commented President and CEO of Nuwellis, Nestor Jaramillo. "Increased awareness of the clinical and economic benefits of the Aquadex system continues to result in healthy utilization gains demonstrating increased therapy adoption as we navigate capital sales cycles. We look forward to continued positive momentum and growth in 2024 as we provide increased access optionality and a new source of revenue with our new 12 cm catheter, advance our pilot phase with DaVita, and begin to commercialize Quelimmune(TM) SCD under our exclusive license and distribution agreement with SeaStar Medical (Nasdaq "ICU")."

Clearmind Medicine (Nasdaq:CMND) stated that it secured the exclusive patent licensing rights from Yissum Research Development Company of the Hebrew University of Jerusalem, which provides Clearmind with global rights to further develop, manufacture, and commercialize compounds that are targeted at treating post-traumatic stress disorder (PTSD) and other mental health conditions.

Dr. Adi Zullof-Shani, CEO of Clearmind, commented, “We are excited to announce this groundbreaking patent license agreement, which reflects our strong collaboration with Yissum and the Hebrew University, a world-leading institution. This agreement marks a significant stride in our mission to meet urgent mental health care needs. We believe that the psychedelic compounds covered by this agreement hold immense promise in treating complex conditions like PTSD, offering a new ray of hope to millions of people worldwide.”

reAlpha Tech (Nasdaq:AIRE) completed its previously announced acquisitions of Naamche, Inc. and Naamche, Inc. Pvt. Ltd.

“This transaction marks a milestone in our strategy to build and scale our capabilities for creating and delivering AI-powered real estate solutions,” commented reAlpha's CEO, Giri Devanur. “We are pleased to integrate Naamche's talented team into our workforce and look forward to our collaboration to continue seeking real-estate focused product innovation.”

“We are excited to join forces with reAlpha and contribute our expertise in AI and technology to help drive innovation in the real estate industry,” stated Ramesh Pathak, CEO of Naamche. “Together, we believe we will be well-positioned to develop cutting-edge solutions for the real estate industry and to modernize its digital landscape.”

For further info, including Kraig Labs disclosure, click here.

The post Lunchtime Pitch appeared first on 24/7 MarketNews.

COMTEX_452017821/2900/2024-05-07T11:55:30